Why Nkarta Stock Is Soaring Today [Yahoo! Finance]
Nkarta, Inc. (NKTX)
Company Research
Source: Yahoo! Finance
This analyst upgrade came after Nkarta provided its second-quarter update on Tuesday. The clinical-stage biopharmaceutical company expects to begin patient enrollment by year-end in an Ntrust-2 clinical trial evaluating experimental natural killer (NK) cell therapy NKX019 in treating autoimmune diseases sclerosis, myositis, and vasculitis. The company also said its cash stockpile of $426.7 million at the end of the second quarter should be enough to fund operations into late 2027. Why is Raymond James more bullish about Nkarta? Raymond James analyst Laura Prendergast likes Nkarta's relatively strong cash position. She noted that the biotech has a market cap lower than its cash on hand. Prendergast also likes the opportunities for NKX019. She believes Nkarta's NK cell therapy could be safer and easier to administer than T-cell therapies. Is Nkarta stock a buy? Clinical-stage biotech stocks are risky, and Nkarta is no exception. Risk-averse investors will be better off stay
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta to Participate in Upcoming Investor ConferenceGlobeNewswire
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at HC Wainwright from $23.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta, Inc. (NASDAQ: NKTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $13.00 price target on the stock.MarketBeat
- Nkarta, Inc. (NASDAQ: NKTX) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $16.00 price target on the stock.MarketBeat
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
NKTX
Earnings
- 8/13/24 - Beat
NKTX
Sec Filings
- 8/23/24 - Form 4
- 8/16/24 - Form 8-K/A
- 8/13/24 - Form 10-Q
- NKTX's page on the SEC website